论文部分内容阅读
目的:探讨~(32)p-玻璃微球(~(32)P-GMS)综合化疗栓塞治疗中晚期原发性肝癌的临床效果。材料与方法:1995年6月～1999年6月,32例中晚期原发性肝癌分为2组,第一组16例,系~(32)P-GMS综合化疗栓塞组,首先注入~(32)P-GMS超液化碘油悬浮液,然后注入3联化疗药,最后用明胶海绵颗粒栓塞第二组16例,系单纯化疗栓塞组。结果:~(32)P-GMS综合化疗栓塞组16例中,9例肿瘤缩小大于50％,6例AFP降至正常,12例生存超过24个月,肿瘤缩小率及AFP下降率两组比较均有显著差异性。~(32)P-GMS综合组12个月、18个月和24个月生存率分别为87.5％、81.0％、75.5％,而单纯化疗栓塞组分别为56％、31％、18.7％,统计学处理亦有显著性差异。结论:~(32)p-GMS是治疗中晚期原发性肝癌可行的内放射性核素之一,采用~(32)P-GMS综合化疗栓塞是提高治疗原发性肝癌患者生存率的有效方法。
Objective: To investigate the clinical efficacy of ~(32)p-glass microspheres (32P-GMS) combined chemoembolization in the treatment of advanced primary liver cancer. Materials and Methods: From June 1995 to June 1999, 32 patients with advanced primary liver cancer were divided into 2 groups. The first group consisted of 16 patients. The patients were treated with 32 P-GMS comprehensive chemoembolization group. 32) P-GMS liquid lipiodol suspension, followed by injection of three chemotherapeutic drugs, and finally embolized in a second group of 16 patients with gelatin sponge granules, a single chemotherapy embolization group. RESULTS: Of the 16 patients who received P-GMS in the 32-P-GMS comprehensive chemotherapy embolization group, the tumor size was reduced by more than 50% in 9 cases, and the AFP was reduced to normal in 6 cases. The survival of 12 cases exceeded 24 months. The tumor shrinkage rate and AFP decrease rate were compared between the two groups. There are significant differences. The 12-, 18-, and 24-month survival rates of the (32)P-GMS comprehensive group were 87.5%, 81.0%, and 75.5%, respectively, whereas those of the chemotherapy-only embolization group were 56%, 31%, and 18.7%, respectively. There are also significant differences in school processing. Conclusions:32 P-GMS is one of the feasible internal radionuclides for the treatment of advanced primary liver cancer. The use of 32 P-GMS combined chemoembolization is an effective method to improve the survival rate of patients with primary liver cancer. .